Cancer — A Predictive Score for Arterial Thrombosis Associated With Cancer
Citation(s)
1 Abdol Razak, N., Jones, G., Bhandari, M., Berndt, M. & Metharom, P. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers (Basel). 10, 380 (2018). 2. Blann, A. D. & Dunmore, S. Arterial and venous thrombosis in cancer patients. Cardiol. Res. Pract. 2011, 394740 (2011). 3. Di Nisio, M. et al. Arterial thrombosis in ambulatory cancer patients treated with chemotherapy. Thromb. Res. 127, 382-383 (2011). 4. Gerotziafas, G. T., Papageorgiou, L., Salta, S., Nikolopoulou, K. & Elalamy, I. Updated clinical models for VTE prediction in hospitalized medical patients. Thromb. Res. 164, S62-S69 (2018). 5. De Stefano, V. Arterial thrombosis and cancer: the neglected side of the coin of Trousseau syndrome. Haematologica 103, 1419-1421 (2018). 6. Aronson, D. & Brenner, B. Arterial thrombosis and cancer. Thromb. Res. 164, S23-S28 (2018). 7. Tuzovic, M. et al. Arterial Thrombosis in Patients with Cancer. Curr. Treat. Options Cardiovasc. Med. 20, 40 (2018). 8. Frere, C., Martin-Toutain, I., Thuny, F. & Bonello, L. Risk of Arterial Thrombosis in Cancer Patients. J. Am. Coll. Cardiol. 71, 260 (2018). 9. Hung, Y.-S. et al. Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy. Cancers (Basel). 10, (2018). 10. Navi, B. B. et al. Risk of Arterial Thromboembolism in Patients With Cancer. J. Am. Coll. Cardiol. 70, 926-938 (2017). 11. Oren, O. & Herrmann, J. Arterial events in cancer patients-the case of acute coronary thrombosis. J. Thorac. Dis. 10, S4367 (2018). 12. Grilz, E. et al. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica 103, 1549-1556 (2018). 13. Baron, J. A., Gridley, G., Weiderpass, E., Nyren, O. & Linet, M. Venous thromboembolism and cancer. Lancet 351, 1077-1080 (1998). 14. Gregson, J. et al. Cardiovascular Risk Factors Associated With Venous Thromboembolism. JAMA Cardiol. 4, 163 (2019). 15. Abdel-Razeq, H. et al. Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! Thromb. J. 16, 2 (2018). 16. Gerotziafas, G. T. et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist 22, 1222-1231 (2017). 17. Antic, D. et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am. J. Hematol. 91, 1014-1019 (2016). 18. Boura, P. et al. PO-53 - Prospective evaluation of risk assessment models and biological markers of hypercoagulability for the identification of high VTE risk patients with lung adenocarcinoma. The ROADMAP study. Thromb. Res. 140, S196 (2016). 19. Anand, L. N. et al. External validation of the COMPASS-Cancer Associated Thrombosis Study: A predictive score to identify patients with solid tumors on treatment who are at risk for venous thromboembolism. J. Clin. Oncol. 37, e18005-e18005 (2019). 20. WHO | International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). WHO (2019). 21. Austin, P. C. & Steyerberg, E. W. Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models. Stat. Methods Med. Res. 26, 796 (2017).
A Predictive Score for Arterial Thrombosis Associated With Cancer. The Prospective COMPASS- Arterial Cancer Associated Thrombosis Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
